跳至主要内容
临床试验/NCT00482963
NCT00482963
已完成
1 期

A Pilot Study of the Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Plan B, and Efavirenz

University of Colorado, Denver2 个研究点 分布在 1 个国家目标入组 24 人2007年5月

概览

阶段
1 期
干预措施
levonorgestrel, efavirenz
疾病 / 适应症
HIV Infections
发起方
University of Colorado, Denver
入组人数
24
试验地点
2
主要终点
The change in Plan B (levonorgestrel) Area under the Concentration Time Curve (AUC12) prior to and during steady state efavirenz
状态
已完成
最后更新
12年前

概览

简要总结

The purpose of this study is to determine if blood levels of the hormonal emergency contraceptive agent, Plan B, are altered by concomitant use with the HIV medication, efavirenz.

详细描述

The use of hormonal contraceptive pills in women with HIV is complex due to potential interactions between these agents and HIV medications. HIV-infected women taking efavirenz have an even greater need for effective birth control as this medication may cause severe brain damage to a developing fetus. The use of an emergency contraceptive agent in cases of unprotected sex or condom failure can prevent pregnancy. This study seeks to establish that Plan B can be used effectively and safely in women taking efavirenz.

注册库
clinicaltrials.gov
开始日期
2007年5月
结束日期
2008年12月
最后更新
12年前
研究类型
Interventional
研究设计
Single Group
性别
Female

研究者

责任方
Sponsor

入排标准

入选标准

  • Healthy, HIV-1 seronegative women of child-bearing age.

排除标准

  • Current use of hormonal contraception
  • Pregnancy/Breast Feeding
  • Post-menopausal status
  • Hepatitis B or C
  • Psychiatric illness
  • Active Substance Abuse

研究组 & 干预措施

levonorgestrel, efavirenz

healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz

干预措施: levonorgestrel, efavirenz

结局指标

主要结局

The change in Plan B (levonorgestrel) Area under the Concentration Time Curve (AUC12) prior to and during steady state efavirenz

时间窗: 12 hour pharmacokinetic study

次要结局

  • Pharmacokinetic parameters of levonorgestrel prior to and during steady state efavirenz(12 hour pharmacokinetic study)
  • Frequency of common levonorgestrel-associated adverse events prior to and during steady-state efavirenz(3 weeks)
  • Changes in liver function tests before and during efavirenz(3 weeks)
  • The efavirenz Area Under the Concentration Time Curve (AUC 24) in setting of levonorgestrel compared to historical controls(12 hour pharmacokinetic study)

研究点 (2)

Loading locations...

相似试验